New drug duo targets hard-to-treat breast cancer in early trial
Disease control
Not yet recruiting
This study tests a combination of two drugs, inavolisib and eribulin, in people with advanced triple-negative breast cancer that has a PIK3CA mutation and has not responded to at least one prior treatment. The goal is to see if the combination shrinks tumors and is safe. About 26…
Phase: PHASE2 • Sponsor: Hu Hai • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC